Royalty Pharma Statistics

Total Valuation

Royalty Pharma has a market cap or net worth of $29.37 billion. The enterprise value is $37.70 billion.

Market Cap	29.37B
Enterprise Value	37.70B

Important Dates

The next confirmed earnings date is Wednesday, May 6, 2026, before market open.

Earnings Date	May 6, 2026
Ex-Dividend Date	May 15, 2026

Share Statistics

Royalty Pharma has 592.82 million shares outstanding. The number of shares has decreased by -4.99% in one year.

Current Share Class	444.38M
Shares Outstanding	592.82M
Shares Change (YoY)	-4.99%
Shares Change (QoQ)	-0.65%
Owned by Insiders (%)	1.36%
Owned by Institutions (%)	81.53%
Float	435.88M

Valuation Ratios

The trailing PE ratio is 27.81 and the forward PE ratio is 9.71. Royalty Pharma's PEG ratio is 1.04.

PE Ratio	27.81
Forward PE	9.71
PS Ratio	12.35
Forward PS	7.92
PB Ratio	3.29
P/TBV Ratio	5.29
P/FCF Ratio	n/a
P/OCF Ratio	11.80
PEG Ratio	1.04

Financial Ratio History

Enterprise Valuation

EV / Earnings	48.90
EV / Sales	15.85
EV / EBITDA	24.12
EV / EBIT	24.17
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.92.

Current Ratio	2.40
Quick Ratio	2.39
Debt / Equity	0.92
Debt / EBITDA	5.74
Debt / FCF	n/a
Interest Coverage	5.07

Financial Efficiency

Return on equity (ROE) is 13.20% and return on invested capital (ROIC) is 5.32%.

Return on Equity (ROE)	13.20%
Return on Assets (ROA)	5.15%
Return on Invested Capital (ROIC)	5.32%
Return on Capital Employed (ROCE)	8.21%
Weighted Average Cost of Capital (WACC)	5.53%
Revenue Per Employee	$23.78M
Profits Per Employee	$7.71M
Employee Count	100
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +53.85% in the last 52 weeks. The beta is 0.39, so Royalty Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.39
52-Week Price Change	+53.85%
50-Day Moving Average	47.07
200-Day Moving Average	40.34
Relative Strength Index (RSI)	61.80
Average Volume (20 Days)	2,743,745

Short Selling Information

The latest short interest is 12.01 million, so 2.03% of the outstanding shares have been sold short.

Short Interest	12.01M
Short Previous Month	11.52M
Short % of Shares Out	2.03%
Short % of Float	2.76%
Short Ratio (days to cover)	3.77

Income Statement

In the last 12 months, Royalty Pharma had revenue of $2.38 billion and earned $770.95 million in profits. Earnings per share was $1.78.

Revenue	2.38B
Gross Profit	2.67B
Operating Income	1.56B
Pretax Income	1.32B
Net Income	770.95M
EBITDA	1.56B
EBIT	1.56B
Earnings Per Share (EPS)	$1.78

Full Income Statement

Balance Sheet

The company has $637.50 million in cash and $8.97 billion in debt, giving a net cash position of -$8.33 billion or -$14.06 per share.

Cash & Cash Equivalents	637.50M
Total Debt	8.97B
Net Cash	-8.33B
Net Cash Per Share	-$14.06
Equity (Book Value)	9.71B
Book Value Per Share	15.11
Working Capital	891.88M

Full Balance Sheet

Cash Flow

Operating Cash Flow	2.49B
Capital Expenditures	n/a
Depreciation & Amortization	3.85M
Net Borrowing	954.48M
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 112.44%, with operating and profit margins of 65.58% and 32.42%.

Gross Margin	112.44%
Operating Margin	65.58%
Pretax Margin	55.68%
Profit Margin	32.42%
EBITDA Margin	65.74%
EBIT Margin	65.58%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of $0.94, which amounts to a dividend yield of 1.90%.

Dividend Per Share	$0.94
Dividend Yield	1.90%
Dividend Growth (YoY)	5.81%
Years of Dividend Growth	6
Payout Ratio	51.08%
Buyback Yield	4.99%
Shareholder Yield	6.89%
Earnings Yield	2.63%
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for Royalty Pharma is $51.40, which is 3.76% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$51.40
Price Target Difference	3.76%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	11.87%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Royalty Pharma has an Altman Z-Score of 1.51 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.51
Piotroski F-Score	6